FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns an agent for prevention and treatment of cardiovascular diseases. The peptide 3-mercaptopropionyl-Phe-Ile-lle-Arg-Lys-Pro-Asp-Lys-NH2 is synthetised which has greater availability and lower price than known analogues; it possesses the antiplatelet, anti-inflammatory and cytoprotective properties.
EFFECT: invention provides reduced spontaneous thrombocyte aggregation, inflammation inhibition by reducing histamine secretion, cell protection against neurotoxic actions of thrombin.
1 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ASSESSING COMPLEX PROTECTION OF CELLS UNDER NEURO-INFLAMMATORY ON IN VITRO MODELS UNDER EXPOSURE TO PAR1 AGONIST | 2022 |
|
RU2796524C1 |
| RECOMBINANT POLYPEPTIDE, METHOD OF INHIBITION OF PLATELET AGGREGATION, RECOMBINANT PLASMID DNA (VARIANTS), RECOMBINANT STRAIN OF ESCHERICHIA COLI (VARIANTS), METHOD OF POLYPEPTIDE PREPARING | 1991 |
|
RU2109816C1 |
| EXTRACELLULAR DOMAIN OF ALPHA SUBUNIT OF IgE Fc RECEPTOR, A PHARMACEUTICAL COMPOSITION CONTAINING IT AND A METHOD FOR ITS PRODUCTION | 2019 |
|
RU2796162C2 |
| NOVEL HUMANISED ANTIBODIES TO FACTOR XI WITH ANTITHROMBOTIC AND ANTI-INFLAMMATORY ACTION AND USE THEREOF | 2020 |
|
RU2817219C2 |
| VARIANTS WITH Fc-FRAGMENT, HAVING HIGH AFFINITY TO FcRn AND HIGH AFFINITY TO AT LEAST ONE RECEPTOR OF Fc-FRAGMENT | 2018 |
|
RU2820162C2 |
| MODIFIED HUMAN ERYTHROPOIETIN | 2019 |
|
RU2827791C2 |
| METHOD FOR NEUROPROTECTION IN EXPERIMENT | 2015 |
|
RU2616509C1 |
| FUSED MOLECULE CAPABLE OF INDUCING NON-INFLAMMATORY PHAGOCYTOSIS | 2022 |
|
RU2823919C1 |
| COMPOSITION CONTAINING PROBIOTICS AND POLYPEPTIDE HAVING BINDING AFFINITY RELATIVELY TO IgE AND ITS USE | 2019 |
|
RU2786578C2 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2743409C2 |
